About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Lung Cancer Mutation Consortium Protocol

NCT01014286·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University of Colorado, Denver

With

National Cancer Institute (NCI)

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. Subjects (=\> 18 years of age) who are undergoing further evaluation for the diagnosis or treatment of advanced adenocarcinoma of the lung.
2. Diagnosed May 2012 or later
3. Oral and written informed consent.

You may not be if

1. Lung cancer histologies other than adenocarcinoma
2. Lack of adequate tissue.

The record

StatusCompleted

PhaseNo phase

Taking part1,100

StartedSep 2009

UpdatedJan 13, 2025

Conditions

Adenocarcinoma of Lung, Stage IV

Where1

University of Colorado Denver Cancer Center
Aurora, Colorado, United States

Clareo Health | Lung Cancer Mutation Consortium Protocol